Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Moderna's Q4 earnings due Feb 14: analysts predict revenue decline & $2.73 loss. Explore vaccine demand, pipeline prospects, and stock outlook.

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and sometimes dangerous source of food poisoning. Moderna’s ...

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older.

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...